Breast Metastasis from Renal Cell Carcinoma: Rare Initial Presentation of Disease Recurrence after 5 Years

Mahrous, Mervat; Morsy, Walid Al; Alhujaily, Ahmed Safar; AL-Sulimani, Sameerah

doi:10.4048/jbc.2012.15.2.244

Cited by 17 publications

(18 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, in approximately 30% of patients, RCC has the propensity to spread to other organs, usually the brain (11%), adrenal glands (15%), liver (41%), bone (42%), lymph nodes (55%), and lungs (70%) [7] , [8] , [9] . Established research studies indicate that metastasis to the breast from extramammary cancer is still less common with primary breast tumors (1%-2% of breast cancers) [10] , [11] , [12] , and RCC metastasis to the breast is rare, occurring only in 3% of all cases [13] , [14] . Traditional cancer therapy, radiation therapy (RT), and chemotherapy are not efficacious in the treatment of advanced breast cancer and RCC [15] .…”

Section: Introductionmentioning

confidence: 99%

Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer

Choi

Jeon

Lee

et al. 2019

Translational Oncology

View full text Add to dashboard Cite

Advanced cancer has been shown to be associated with a higher percentage of epigenetic changes than with genetic mutations. Preclinical models have shown that the combination of paclitaxel, sorafenib, and radiation therapy (RT) plays a crucial role in renal cell carcinoma (RCC) and breast cancer. This study aimed to investigate the involvement of mitochondrial cytochrome c–dependent apoptosis in the mechanism of action of a combination of paclitaxel, sorafenib, and RT in RCC and breast cancer. RCC and breast cancer cell lines were exposed to paclitaxel and sorafenib alone or combined in the presence of radiation, and cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The synergistic anticancer effects of the combination therapy on cell cycle and intracellular signaling pathways were estimated using flow cytometry and immunoblot analysis. RCC and breast cancer cell line xenograft models were used to examine the antitumor activity in vivo. Our results suggest that paclitaxel, sorafenib, and RT synergistically decreased the viability of RCC and breast cancer cells and significantly induced their apoptosis, as shown by caspase-3 cleavage. Paclitaxel, sorafenib, and radiation cotreatment reduced antiapoptotic factor levels in these cells and, thereby, significantly reduced the tumor volume of RCC and breast cancer cell xenografts. The current study suggests that paclitaxel, sorafenib, and radiation cotreatment was more effective than cotreatment with paclitaxel or sorafenib and radiation. These findings may offer a new therapeutic approach to RCC and breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer

Choi

Jeon

Lee

et al. 2019

Translational Oncology

View full text Add to dashboard Cite

show abstract

“…Accurate diagnosis is important to prevent unnecessary radical procedures and to institute an appropriate systemic oncologic therapy. Metastasis from RCC in breast is extremely rare and only few cases have been reported in literature, most of them years after a previous nephrectomy [4,6,7]. Moreover, breast metastasis as first sign of renal disease, as occurs in our patient, is exceptional [2,8].…”

Section: Discussionmentioning

confidence: 99%

“…Vascular invasion is most common pathway of spread and 30% of patients have metastasis at the time of diagnosis, most commonly in lung (70%), lymph-nodes (55%), bone (42%), liver (41%), and central nervous system (11%) [3,4].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Breast Metastasis as Initial Presentation of Silent, Synchronic, Widely Metastatic Renal Cell Carcinoma

Ls¹,

Giménez-Barriga²,

Plaza-Loma³

et al. 2015

JCR

View full text Add to dashboard Cite

Abstract:Metastasis to breast from extra-mammary sites is much less common as compared to primary ones and only few cases are reported in the literature. Furthermore, very little is known about prognosis and treatment of patients with solid neoplasms metastatic to the breast. If a breast lump is found, it is recommended to perform a bilateral mammogram specially when there is a rapidly enlargement. Here, we describe a case of a young woman with synchronic breast metastasis from asymptomatic, widely spread, renal cell carcinoma, Furhman grade 4. RCC is one of the most aggressive urologic tumors and rarely metastasizes to the breast. This phenomenon takes place in less than 3% of all metastatic renal cell carcinoma and the appearance as first sign of renal disease is exceptional. This case illustrates the importance of histopathological investigation in a breast mass and the potential for rare sites of metastasis in order to prevent unnecessary radical procedures. Also, this report contributes to importance of a proper diagnosis when rare sites of metastatic deposit, like breast, are detected, especially if there is no previous history of neoplasm.

show abstract

“…Parotid metastases of RCC are rare, with a review in 2008 identifying only 26 cases of RCC metastasizing to the parotid [15] . Metastases to the breast from RCC are also rare, reported in 3% of all metastatic RCC [16] with overall 25 cases reported in the literature (11 cases presenting with metastasis as the initial sign of the disease and 14 occurring as metachronous lesions after prior nephrectomy) [17,18] . Testicular metastasis from RCC is extremely rare.…”

Section: Discussionmentioning

confidence: 99%

Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents

et al. 2017

View full text Add to dashboard Cite

Purpose: Pancreatic metastases (PM) from renal cell carcinoma (RCC) have been associated with long-term survival. The aim of this study was to evaluate the outcome of RCC patients with multiple glandular metastases (MGM) treated with targeted therapies (TTs). Methods: Sixty-four MGM patients treated between 1993 and 2014 were retrospectively identified from a database of 274 RCC patients with PM from 11 European centers. The survival of MGM patients was compared with that of both patients with PM only and a cohort of 325 RCC patients with non-GM (control group) treated with TTs. Survival was estimated using the Kaplan-Meier method and was statistically compared using the log-rank test. Results: Fifty-six patients (88%) had at least 2 MGM, 7 patients (11%) had 3 MGM and 1 patient had 4 MGM, while non-GM were present in the remaining patients. The median overall survival (OS) was 54.2 months for MGM and 73.4 months for patients with PM only. The median OS in the control group was 22.7 months and statistically inferior to both MGM (p < 0.001) and PM patients (p < 0.001). Conclusion: MGM from RCC are associated with a remarkable survival. Despite some limitations, these findings suggest that GM might be considered a predictor of a favorable prognosis.

show abstract

Breast Metastasis from Renal Cell Carcinoma: Rare Initial Presentation of Disease Recurrence after 5 Years

Cited by 17 publications

References 12 publications

Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer

Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer

Breast Metastasis as Initial Presentation of Silent, Synchronic, Widely Metastatic Renal Cell Carcinoma

Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents

Contact Info

Product

Resources

About